Evidence map›Paper›PMID 36551754›Full record

ArticleCancers2022

Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression.

Matteo Ponzo, Anais Debesset, Mélissande Cossutta, Mounira Chalabi-Dchar, Claire Houppe, Caroline Pilon, Alba Nicolas-Boluda, Sylvain Meunier, Fabio Raineri, Allan Thiolat and 12 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 75% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 2 countries.

Matteo PonzoImmune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France.
Anais DebessetImmune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France.
Mélissande CossuttaImmune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France.ORCID 0000-0001-5460-8386
Mounira Chalabi-DcharCancer Research Center of Lyon, Cancer Cell Plasticity Department, University of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, F-69008 Lyon, France.ORCID 0000-0002-4539-589X
Claire HouppeImmune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France.
Caroline PilonImmune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France.
Alba Nicolas-BoludaMatières et Systèmes Complexes (MSC), Université de Paris, CNRS UMR 7057, F-75006 Paris, France.
Sylvain MeunierImmune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France.
Fabio RaineriImmune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France.ORCID 0000-0002-7049-0944
Allan ThiolatImmune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France.
Rémy NicolleProgramme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, F-75013 Paris, France.ORCID 0000-0001-8084-1173
Federica MaioneLaboratory of Tumor Microenvironment, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
Serena BrunduLaboratory of Tumor Microenvironment, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.ORCID 0000-0003-4468-7492
Carina Florina CojocaruLaboratory of Tumor Microenvironment, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.ORCID 0000-0003-2340-6559
Philippe BouvetMatières et Systèmes Complexes (MSC), Université de Paris, CNRS UMR 7057, F-75006 Paris, France.ORCID 0000-0003-4524-2233
Corinne BousquetUMR INSERM-1037, Cancer Research Center of Toulouse (CRCT), Toulouse University III, F-31037 Toulouse, France.
Florence GazeauAP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre D'investigation Clinique Biothérapie, F-94010 Créteil, France.
Christophe TournigandImmune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France.
José CourtyImmune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France.
Enrico GiraudoLaboratory of Tumor Microenvironment, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.ORCID 0000-0003-4128-4786
José L CohenImmune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France.ORCID 0000-0002-5077-6726
Ilaria CasconeImmune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France.ORCID 0000-0003-4903-8926
Inserm · FRCandiolo Cancer Institute · ITUniversité Claude Bernard Lyon 1 · FRAssistance Publique – Hôpitaux de Paris · FRCentre National de la Recherche Scientifique · FRLa Ligue Contre le Cancer · FR

Funding

Agence Nationale de la Recherche TheranucFrench National Cancer Institute PRTK IMPROVE ICIsItalian Association for Cancer Research 21052Italian Association for Cancer Research IG-19957
6 · The paper itself

Abstract

In the original publication [...].

Identifiers

PMID36551754
PMCPMC9776549
OpenAlexW4311378556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.